Sanofi Slams Mylan's 'Mishmash' Of Claims Over Insulin
By Carla Baranauckas ( September 18, 2023, 4:54 PM EDT) -- Sanofi-Aventis U.S. is asking a Pennsylvania federal court to toss Mylan Pharmaceuticals' claims that Sanofi abused discounts and patent litigation to keep Mylan's generic injectable insulin off the market, arguing Mylan's antitrust complaint amounts to a "mishmash" of allegations that fall short of pleading standards for Sherman Act suits....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.